Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8 + T cells

Nature Immunology

Volumn 16, Issue 6, 2015, Pages 609-617

  Carretero, Rafael ^a   Sektioglu, Ibrahim M ^a   Garbi, Natalio ^a,c   Salgado, Oscar C ^a   Beckhove, Philipp ^a,b   Hämmerling, Günter J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; DIPHTHERIA TOXIN; ENHANCED GREEN FLUORESCENT PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; CHEMOTACTIC FACTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HOMING; CELL SURVIVAL; CONTROLLED STUDY; EOSINOPHIL; EOSINOPHILIA; FLOW CYTOMETRY; IN VITRO STUDY; LYMPHOCYTE MIGRATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REJECTION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANGIOGENESIS; ANIMAL; BLOOD VESSEL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; CELL MOTION; CYTOTOXICITY; EXPERIMENTAL MELANOMA; IMMUNOLOGY; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); SKIN TUMOR; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CHEMOTACTIC FACTORS; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHILS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN NEOPLASMS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84929965822     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3159     Document Type: Article

References (48)

1. Rothenberg, M. E. & Hogan, S. P. The eosinophil. Annu. Rev. Immunol. 24, 147-174 (2006).
2. Rosenberg, H. F. , Dyer, K. D. & Foster, P. S. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol. 13, 9-22 (2013).
3. Kita, H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol. Rev. 242, 161-177 (2011).
4. Melo, R. C. , Liu, L. , Xenakis, J. J. & Spencer, L. A. Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion. Allergy 68, 274-284 (2013).
5. Reinbach, G. Ueber das Verhalten der Leukocyten bei malignen Tumoren. Arch. Klin. Chir 46, 486-562 (1893).
6. Simson, L. et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol. 178, 4222-4229 (2007).
7. Cormier, S. A. et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 79, 1131-1139 (2006).
8. Lotfi, R. et al. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J. Immunol. 183, 5023-5031 (2009).
9. Lotfi, R. , Lee, J. J. & Lotze, M. T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 30, 16-28 (2007).
10. Davis, B. P. & Rothenberg, M. E. Eosinophils and cancer. Cancer Immunol. Res. 2, 1-8 (2014).
11. Gatault, S. , Legrand, F. , Delbeke, M. , Loiseau, S. & Capron, M. Involvement of eosinophils in the anti-tumor response. Cancer Immunol. Immunother. 61, 1527-1534 (2012).
12. Tepper, R. I. , Coffman, R. L. & Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551 (1992).
13. Golumbek, P. T. et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716 (1991).
14. Noffz, G. , Qin, Z. , Kopf, M. & Blankenstein, T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J. Immunol. 160, 345-350 (1998).
15. Mattes, J. et al. Immunotherapy of cytotoxic T cell-resistant tumors by Thelper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197, 387-393 (2003).
16. Samoszuk, M. et al. Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice. Am. J. Pathol. 165, 449-456 (2004).
17. Krüger-Krasagakes, S. , Li, W. , Richter, G. , Diamantstein, T. & Blankenstein, T. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth. Eur. J. Immunol. 23, 992-995 (1993).
18. Huland, E. & Huland, H. Tumor-associated eosinophilia in interleukin-2-treated patients: Evidence of toxic eosinophil degranulation on bladder cancer cells. J. Cancer Res. Clin. Oncol. 118, 463-467 (1992).
19. Sosman, J. A. et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: Effects of interleukin-4 alone and following interleukin-2 administration. Clin. Cancer Res. 1, 805-812 (1995).
20. Galdiero, M. R. et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology 218, 1402-1410 (2013).
21. Li, X. , Kostareli, E. , Suffner, J. , Garbi, N. & Hammerling, G. J. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40, 3325-3335 (2010).
22. Zimmermann, N. et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63, 1156-1163 (2008).
23. Chu, V. T. et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 12, 151-159 (2011).
24. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414 (2008).
25. Munitz, A. & Levi-Schaffer, F. Eosinophils: 'new' roles for 'old' cells. Allergy 59, 268-275 (2004).
26. Restifo, N. P. , Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
27. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
28. Dalton, D. K. et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259, 1739-1742 (1993).
29. Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818 (2008).
30. Stockmann, C. , Schadendorf, D. , Klose, R. & Helfrich, I. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front. Oncol. 4, 69 (2014).
31. Huang, Y. , Goel, S. , Duda, D. G. , Fukumura, D. & Jain, R. K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943-2948 (2013).
32. Ganss, R. , Ryschich, E. , Klar, E. , Arnold, B. & Hammerling, G. J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462-1470 (2002).
33. Ryschich, E. , Schmidt, J. , Hammerling, G. J. , Klar, E. & Ganss, R. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 97, 719-725 (2002).
34. Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475, 226-230 (2011).
35. Gabrilovich, D. I. , Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
36. Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589-602 (2013).
37. Garbi, N. , Arnold, B. , Gordon, S. , Hammerling, G. J. & Ganss, R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172, 5861-5869 (2004).
38. Finlay, D. K. et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 209, 2441-2453 (2012).
39. Shi, S. et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE 8, e65757 (2013).
40. Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 109, 17561-17566 (2012).
41. Liu, L. Y. et al. Generation of Th1 and Th2 chemokines by human eosinophils: Evidence for a critical role of TNF. J. Immunol. 179, 4840-4848 (2007).
42. Wu, D. et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332, 243-247 (2011).
43. Delyon, J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24, 1697-1703 (2013).
44. Motz, G. T. & Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 39, 61-73 (2013).
45. Fridman, W. H. et al. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 71, 5601-5605 (2011).
46. Suffner, J. et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3. LuciDTR mice. J. Immunol. 184, 1810-1820 (2010).
47. Kohlmeyer, J. et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69, 6265-6274 (2009).
48. Domschke, C. et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 69, 8420-8428 (2009).